Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Statins: a new approach to combat temozolomide chemoresistance in glioblastoma.

Shojaei S, Alizadeh J, Thliveris J, Koleini N, Kardami E, Hatch GM, Xu F, Hombach-Klonisch S, Klonisch T, Ghavami S.

J Investig Med. 2018 Dec;66(8):1083-1087. doi: 10.1136/jim-2018-000874. Epub 2018 Oct 27.

PMID:
30368483
2.

Annexin A5 promotes invasion and chemoresistance to temozolomide in glioblastoma multiforme cells.

Wu L, Yang L, Xiong Y, Guo H, Shen X, Cheng Z, Zhang Y, Gao Z, Zhu X.

Tumour Biol. 2014 Dec;35(12):12327-37. doi: 10.1007/s13277-014-2545-1. Epub 2014 Sep 23.

PMID:
25245332
3.

Role of miR-223/paired box 6 signaling in temozolomide chemoresistance in glioblastoma multiforme cells.

Cheng Q, Ma X, Cao H, Chen Z, Wan X, Chen R, Peng R, Huang J, Jiang B.

Mol Med Rep. 2017 Feb;15(2):597-604. doi: 10.3892/mmr.2016.6078. Epub 2016 Dec 27.

4.

Investigating a signature of temozolomide resistance in GBM cell lines using metabolomics.

St-Coeur PD, Poitras JJ, Cuperlovic-Culf M, Touaibia M, Morin P Jr.

J Neurooncol. 2015 Oct;125(1):91-102. doi: 10.1007/s11060-015-1899-6. Epub 2015 Aug 28.

PMID:
26311249
5.

Hyperoxia resensitizes chemoresistant glioblastoma cells to temozolomide through unfolded protein response.

Lee D, Sun S, Ho AS, Kiang KM, Zhang XQ, Xu FF, Leung GK.

Anticancer Res. 2014 Jun;34(6):2957-66.

PMID:
24922660
6.

A Metabolic Inhibitory Cocktail for Grave Cancers: Metformin, Pioglitazone and Lithium Combination in Treatment of Pancreatic Cancer and Glioblastoma Multiforme.

Elmaci İ, Altinoz MA.

Biochem Genet. 2016 Oct;54(5):573-618. doi: 10.1007/s10528-016-9754-9. Epub 2016 Jul 4. Review.

PMID:
27377891
7.

A tumor-targeting p53 nanodelivery system limits chemoresistance to temozolomide prolonging survival in a mouse model of glioblastoma multiforme.

Kim SS, Rait A, Kim E, Pirollo KF, Chang EH.

Nanomedicine. 2015 Feb;11(2):301-11. doi: 10.1016/j.nano.2014.09.005. Epub 2014 Sep 18.

8.

Distance to the neurooncological center: a negative prognostic factor in patients with glioblastoma multiforme. An epidemiological study.

Kerschbaumer J, Freyschlag CF, Bauer R, Obwegeser AA, Schubert GA, Thomé C, Seiz M.

Anticancer Res. 2012 Dec;32(12):5515-9.

PMID:
23225460
9.

Tamoxifen in combination with temozolomide induce a synergistic inhibition of PKC-pan in GBM cell lines.

Balça-Silva J, Matias D, do Carmo A, Girão H, Moura-Neto V, Sarmento-Ribeiro AB, Lopes MC.

Biochim Biophys Acta. 2015 Apr;1850(4):722-32. doi: 10.1016/j.bbagen.2014.12.022. Epub 2014 Dec 29.

PMID:
25554223
10.

An Interplay between Senescence, Apoptosis and Autophagy in Glioblastoma Multiforme-Role in Pathogenesis and Therapeutic Perspective.

Pawlowska E, Szczepanska J, Szatkowska M, Blasiak J.

Int J Mol Sci. 2018 Mar 17;19(3). pii: E889. doi: 10.3390/ijms19030889. Review.

11.

Current trends in glioblastoma multiforme treatment: radiation therapy and immune checkpoint inhibitors.

Nicholas S, Mathios D, Ruzevick J, Jackson C, Yang I, Lim M.

Brain Tumor Res Treat. 2013 Apr;1(1):2-8. doi: 10.14791/btrt.2013.1.1.2. Epub 2013 Apr 30. Review.

12.

Impact of human cytomegalovirus on glioblastoma cell viability and chemotherapy treatment.

Dos Santos CJ, Ferreira Castro FL, de Aguiar RB, Menezes IG, Santos AC, Paulus C, Nevels M, Carlan da Silva MC.

J Gen Virol. 2018 Sep;99(9):1274-1285. doi: 10.1099/jgv.0.001118. Epub 2018 Jul 27.

PMID:
30045780
13.

MicroRNA-101 reverses temozolomide resistance by inhibition of GSK3β in glioblastoma.

Tian T, Mingyi M, Qiu X, Qiu Y.

Oncotarget. 2016 Nov 29;7(48):79584-79595. doi: 10.18632/oncotarget.12861.

14.

Cordycepin Augments the Chemosensitivity of Human Glioma Cells to Temozolomide by Activating AMPK and Inhibiting the AKT Signaling Pathway.

Bi Y, Li H, Yi D, Sun Y, Bai Y, Zhong S, Song Y, Zhao G, Chen Y.

Mol Pharm. 2018 Nov 5;15(11):4912-4925. doi: 10.1021/acs.molpharmaceut.8b00551. Epub 2018 Oct 17.

PMID:
30336060
15.

Effectiveness of temozolomide treatment used at the same time with radiotherapy and adjuvant temozolomide; concomitant therapy of glioblastoma multiforme: multivariate analysis and other prognostic factors.

Birol Sarica F, Tufan K, Cekinmez M, Sen O, Cem Onal H, Mertsoylu H, Topkan E, Pehlivan B, Erdogan B, Nur Altinors M.

J Neurosurg Sci. 2010 Mar;54(1):7-19.

PMID:
20436394
16.

Metformin and temozolomide, a synergic option to overcome resistance in glioblastoma multiforme models.

Valtorta S, Lo Dico A, Raccagni I, Gaglio D, Belloli S, Politi LS, Martelli C, Diceglie C, Bonanomi M, Ercoli G, Vaira V, Ottobrini L, Moresco RM.

Oncotarget. 2017 Dec 6;8(68):113090-113104. doi: 10.18632/oncotarget.23028. eCollection 2017 Dec 22.

17.

Clinical impact of adjuvant chemotherapy in glioblastoma multiforme : a meta-analysis.

Spiegel BM, Esrailian E, Laine L, Chamberlain MC.

CNS Drugs. 2007;21(9):775-87. Review.

PMID:
17696576
18.

MALAT1 is a prognostic factor in glioblastoma multiforme and induces chemoresistance to temozolomide through suppressing miR-203 and promoting thymidylate synthase expression.

Chen W, Xu XK, Li JL, Kong KK, Li H, Chen C, He J, Wang F, Li P, Ge XS, Li FC.

Oncotarget. 2017 Apr 4;8(14):22783-22799. doi: 10.18632/oncotarget.15199.

19.

MicroRNA-210 and Endoplasmic Reticulum Chaperones in the Regulation of Chemoresistance in Glioblastoma.

Lee D, Sun S, Zhang XQ, Zhang PD, Ho AS, Kiang KM, Fung CF, Lui WM, Leung GK.

J Cancer. 2015 Jan 16;6(3):227-32. doi: 10.7150/jca.10765. eCollection 2015.

20.

Human glioblastoma multiforme: p53 reactivation by a novel MDM2 inhibitor.

Costa B, Bendinelli S, Gabelloni P, Da Pozzo E, Daniele S, Scatena F, Vanacore R, Campiglia P, Bertamino A, Gomez-Monterrey I, Sorriento D, Del Giudice C, Iaccarino G, Novellino E, Martini C.

PLoS One. 2013 Aug 19;8(8):e72281. doi: 10.1371/journal.pone.0072281. eCollection 2013.

Supplemental Content

Support Center